A Bacterial Killcode Against Cancer

  • Author: Ann-Christin Hau
  • Published: 20 February 2017
  • Copyright: Wiley-VCH Verlag GmbH & Co. KGaA
  • Source / Publisher: Molecular Therapy Oncolytics/Elsevier
thumbnail image: A Bacterial Killcode Against Cancer

Glioblastoma is the most common and aggressive solid brain tumor with a mean life expectancy of only 12 to 15 months in patients. Standard medical care includes surgical resection, radiation, and systemic chemotherapy. Unfortunately, due to the diffuse growth and highly infiltrative capacities of the cancer cells, standard therapy is often not enough and patients suffer from tumor relapse.

To date, major treatment obstacles of a systemic chemotherapeutic approach are the natural diffusion barriers of solid tumors preventing the delivery of accurate doses of cancer drugs. In addition, currently used strategies such as pressure-gradient infusion of drugs are accompanied by serious side-effects that can cause long-lasting damage to the healthy brain.

Ravi V. Bellamkonda, Duke University, Durham, NC, USA, and colleagues have designed a drug delivery strategy based on a non-pathogenic strain of the gut bacteria Salmonella typhimurium. The advantage of this approach is the higher motility that bacterial vehicles can achieve within the tumor. This increased motility leads to an improved delivery of the anticancer treatment. The scientists exploit a biological feature of tumor cells, e.g. their richness in purines, to target purine-deficient bacterial carriers more specifically to tumor cells.

To eliminate tumor cells, the bacteria are loaded with a specific killcode in form of DNA, coding for tumoricidal proteins such as the tumor suppressor protein p53 and/or Azurin. The expression of those proteins was put under the control of a promoter that will be turned on under hypoxic conditions, which reflects the microenvironment present within brain tumors. The researchers could demonstrate that tumor-bearing mice treated with bacterial vesicles showed an overall survival benefit of 19 % compared with non-treated mice.


Article Views: 1600

Sign in Area

Please sign in below

Additional Sign In options

Please note that to comment on an article you must be registered and logged in.
Registration is for free, you may already be registered to receive, e.g., the newsletter. When you register on this website, please ensure you view our terms and conditions. All comments are subject to moderation.

Article Comments - To add a comment please sign in

Bookmark and Share

If you would like to reuse any content, in print or online, from ChemistryViews.org, please contact us first for permission. more


ChemistryViews.org on Facebook

ChemistryViews.org on Twitter ChemistryViews.org on YouTube ChemistryViews.org on LinkedIn Sign up for our free newsletter

A product of ChemPubSoc Europe (16 European Chemical Societies)and Wiley-VCH